NewAmsterdam Operating Cycle from 2010 to 2026

NAMSW Stock   23.95  0.85  3.68%   
NewAmsterdam Pharma Operating Cycle yearly trend continues to be fairly stable with very little volatility. Operating Cycle will likely drop to 87.76 in 2026. During the period from 2010 to 2026, NewAmsterdam Pharma Operating Cycle regression line of quarterly data had mean square error of  1,032 and geometric mean of  58.10. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
153.6
Current Value
87.76
Quarterly Volatility
38.10756467
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check NewAmsterdam Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewAmsterdam Pharma's main balance sheet or income statement drivers, such as Net Interest Income of 20.4 M, Interest Income of 20.4 M or Depreciation And Amortization of 136.4 K, as well as many indicators such as Price To Sales Ratio of 32.1, Dividend Yield of 0.0 or PTB Ratio of 1.82. NewAmsterdam financial statements analysis is a perfect complement when working with NewAmsterdam Pharma Valuation or Volatility modules.
  
Build AI portfolio with NewAmsterdam Stock
Check out the analysis of NewAmsterdam Pharma Correlation against competitors.
For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.

Latest NewAmsterdam Pharma's Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of NewAmsterdam Pharma over the last few years. It is NewAmsterdam Pharma's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NewAmsterdam Pharma's overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Slightly volatile
   Operating Cycle   
       Timeline  

NewAmsterdam Operating Cycle Regression Statistics

Arithmetic Mean64.37
Geometric Mean58.10
Coefficient Of Variation59.21
Mean Deviation25.76
Median48.73
Standard Deviation38.11
Sample Variance1,452
Range122
R-Value0.58
Mean Square Error1,032
R-Squared0.33
Significance0.02
Slope4.36
Total Sum of Squares23,235

NewAmsterdam Operating Cycle History

2026 87.76
2025 153.6
2024 170.67

About NewAmsterdam Pharma Financial Statements

NewAmsterdam Pharma investors use historical fundamental indicators, such as NewAmsterdam Pharma's Operating Cycle, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NewAmsterdam Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Operating Cycle 153.60  87.76 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.